Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 26/5/2017
SIETES contiene 91804 citas

 
 
 1 a 20 de 1761 siguiente >>
Presentar resultados
Seleccionar todas
1.Tiene citas relacionadas Cita con resumen
Curfman G. Risks of statin therapy in older adults. JAMA Intern Med 2017:22 de mayo. [Ref.ID 101591]
2.Tiene citas relacionadas Cita con resumen
Han BH, Sutin D, Williamson JD, Davis BR, Piller LB, Pervin H, Pressel SL, Blaum CS, for the ALLHAT Collaborative Research Group. Effect of statin treatment vs usual care on primary cardiovascular prevention among older adults. The ALLHAT-LLT randomized clinical trial. JAMA Intern Med 2017:22 de mayo. [Ref.ID 101590]
4. Cita con resumen
Greenway T, Ross JS. US drug marketing: how does promotion correspond with health value?. BMJ 2017;357:j1855. [Ref.ID 101571]
5. Cita con resumen
Larkin I, Ang D, Steinhart J, Chao M, Patterson M, Sah S, Wu T, Schoen-baum M, Hutchins D, Brennan T, Loewen-stein G. Association between academic medical center pharmaceutical detailing policies and physician prescribing. JAMA 2017;317:1785-95. [Ref.ID 101559]
6. Cita con resumen
Chobanian AV. Hypertension in 2017- What is the right target?. JAMA 2017;317:579-80. [Ref.ID 101415]
7. Cita con resumen
McGettigan P, Ferner RE. PCSK9 inhibitors for hypercholesterolaemia. BMJ 2017;356:j188. [Ref.ID 101397]
8. Cita con resumen
Khan AR, Bavishi C, Riaz H, Farid TA, Khan S, Atlas M, Hirsch G, Ikram S, Bolli R. Increased risk of adverse neurocognitive outcomes with proprotein convertase subtilisin-kexin type 9 inhibitors. Circulation: Cardiovascular Quality and Outcomes 2017;10:e003153. [Ref.ID 101377]
9. Cita con resumen
Nicholls SJ, Puri R, Anderson T, Ballantyne CM, Cho L, Kastelein JJ, Koenig W, Somaratne R, Kassahun H, Yang J, Wasserman SM, Scott R, Unqi I, Podolec J, Ophuis AO, Cornel JH, Borgman M, Brennan DM, Nissen SE. Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAVOV randomized clinical trial. JAMA 2016;316:2373-84. [Ref.ID 101030]
11.Enlace a cita originalTiene citas relacionadas
12.Enlace a cita originalTiene citas relacionadas
Redberg RF, Katz MH. Statins for primary prevention: the debate is intense, but the data are weak. JAMA 2016;316:1979-81. [Ref.ID 100987]
13.Enlace a cita originalTiene citas relacionadas
Greenland P, Bonow RO. Interpretation and use of another statin guideline. JAMA 2016;316:1977-9. [Ref.ID 100986]
14.Enlace a cita originalTiene citas relacionadas
Gurwitz JH, Go AS, Fortmann SP. Statins for primary prevention in older adults: uncertainty and the need for more evidence. JAMA 2016;316:1971-2. [Ref.ID 100985]
15.Enlace a cita originalTiene citas relacionadas
Thompson PD. What to believe and do about statin-associated adverse efects. JAMA 2016;316:1969-70. [Ref.ID 100984]
16.Enlace a cita originalTiene citas relacionadas
Rodríguez F, Harrington RA. Cholesterol, cardiovascular risk, statins, PCSK9 inhibitors, and the future of LDL-C lowering. JAMA 2016;316:1967-8. [Ref.ID 100983]
18. Cita con resumen
Silverman MG, Ference BA, Im K, Wiviott SD, Giugliano RP, Grundy SM, Braunwald E, Sabatine MS. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. JAMA 2016;316:1289-97. [Ref.ID 100769]
19. Cita con resumen
Godlee F. Statins: we need an independent review. BMJ 2016;354:i4992. [Ref.ID 100746]
20. Cita con resumen
Leibowitz M, Karpati T, Cohen-Stavi CJ, Feldman BS, Hoshen M, Bitterman H, Suissa S, Balicer RD. Association between achieved low-density lipoprotein levels and major adverse cardiac events in patients with stable ischemic heart disease taking statin treatment. JAMA Intern Med 2016;176:1105-13. [Ref.ID 100700]
Seleccionar todas
 
 1 a 20 de 1761 siguiente >>